Analysts’ Opinions Are Mixed on These Healthcare Stocks: Novavax (NVAX), Xenon (XENE) and Biohaven Ltd. (BHVN)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Novavax (NVAX – Research Report), Xenon (XENE – Research Report) and Biohaven Ltd. (BHVN – Research Report).
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Novavax (NVAX)
Bank of America Securities analyst Alec Stranahan maintained a Sell rating on Novavax on December 26 and set a price target of $6.00. The company’s shares closed last Friday at $6.83, close to its 52-week low of $3.81.
According to TipRanks.com, Stranahan is a 4-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Novavax with a $10.00 average price target.
See the top stocks recommended by analysts >>
Biohaven Ltd. (BHVN)
In a report issued on December 26, Tessa Romero from J.P. Morgan maintained a Buy rating on Biohaven Ltd.. The company’s shares closed last Friday at $11.15.
According to TipRanks.com, Romero is a 5-star analyst with an average return of
Currently, the analyst consensus on Biohaven Ltd. is a Moderate Buy with an average price target of $15.09, a 56.0% upside from current levels. In a report issued on December 25, Leerink Partners also maintained a Buy rating on the stock with a $15.00 price target.
